DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March 24, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) ...
"We are excited to initiate the Phase 3 study and we believe that Piclidenoson's oral dosage and excellent safety record, ...
Biosimilars are essential healthcare equalizers, but their regulation is overly complicated due to lobbying by makers of ...
Although the regulatory landscape for advanced therapy medicinal products (ATMPs) is rapidly evolving, varying regulatory ...
FDA & EMA approvals for rare genetic diseases are fast and require clinical studies with small number of patients Ramat Gan, Israel, March ...
6d
Namodenoson, has been also granted Orphan Drug Designation by the FDA for pancreatic cancer. The designation as an orphan drug will provide, among others, potential for market exclusivity for seven ...
Q4 2024 Earnings Call Transcript March 17, 2025 Protalix BioTherapeutics, Inc. beats earnings expectations. Reported EPS is $0.09, expectations were $0.07. Operator: Good morning, ladies and gentlemen ...
Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...
Cytokinetics is now rapidly moving into commercialization efforts with Aficamten. Read more to see why I rate CYTK stock a ...
The study found that just 20% of trials submitted to both the FDA and European Medicines Agency had matching evidence.
DelveInsight's "BAVENCIO Market Size, Forecast, and Market Insight Report" highlights the details around BAVENCIO, a human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback